Zurich-based Mabylon, a Swiss biotech scale-up, secured €31.8 million in new funding. This Mabylon funding round will advance its lead peanut allergy program. The investment, comprising a capital increase and a convertible loan, came from existing private investors. Former management and board members of Roche provided the major investment.
Advancing Allergy Antibody Pipeline
Mabylon will use the funds to advance its lead program, MY006, a tri-specific antibody targeting peanut allergens. The company aims to complete a Phase Ia/b trial for MY006 by 2027, generating safety and preliminary efficacy data. This biotech innovation focuses on a high unmet medical need.
The funding also supports Mabylon's early-stage pipeline development. This includes MY010, a multi-specific antibody for birch and related tree, fruit, and nut allergens. Additionally, MY011, an antibody product for grass pollen allergies, will see further development.
Mabylon specializes in human-derived antibodies for allergies, neurodegenerative diseases, and inflammation.
The company believes human-derived antibodies offer superior therapeutic potential compared to conventional sources. This significant Mabylon funding enables further antibody discovery and development. Mabylon's approach expands knowledge of novel allergenic epitopes, positioning it alongside companies like Novartis and Sanofi.
